The U.S. Department of Health and Human Services (HHS), through the Administration for Strategic Preparedness and Response (ASPR), today announced it awarded more than $1.4 billion for Project NextGen.
This award supports the development of a new generation of tools and technologies to protect people against COVID-19 for years to come.
$1.4 Billion for NextGen COVID-19 Vaccines and Therapeutics
Expecting Mothers Have RSV Prevention Options
As the 2023 RSV season begins to accelerate in the United States, pregnant women have two options to protect their child from the Respiratory Syncytial Virus (RSV).
Over the past month, the U.S. Food and Drug Administration (FDA) approved an RSV monoclonal antibody (mAb) and vaccine to protect infants from RSV.
On August 21, 2023, the FDA approved the first vaccine for pregnant women to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth through 6 months.
COVID-19 Recession Resulted in ‘Baby Bump’
Relative to prepandemic trend, births to U.S. mothers decreased by 31,000 in 2020 but increased by 71,000 in 2021